12th ICML Highlights in Lymphoma

Dr. Peter Borchmann discusses how discrimination of an early unfavorable risk group has significant impact on treatment outcome in early stage Hodgkin lymphoma.
Dr. Robert Chen discusses the findings from his clinical trial with Brentuximab vedotin and reduced-intensity allogeneic transplant in relapsed or refractory Hodgkin lymphoma.
Dr. Andrew Evens discusses clinical trials and comorbidities specific to the treatment of Hodgkin lymphoma in the elderly.
Dr. Mary Gospodarowicz discusses if radiation therapy should be a part of the standard therapy for stage 1 and 2 Hodgkin lymphoma.
Prof. Tim Illidge discusses the role of radiation therapy in the treatment of Hodgkin lymphoma.
Dr. Peter Johnson discusses the results from the international response adapted therapy in advanced HL (RATHL) study, responses and chemotherapy dose adjustment determined by PET-CT imaging.
Dr. James Armitage discusses the latest updates in the treatment of Hodgkin lymphoma.
Dr. James Armitage provides an overview of the 12th International Conference on Malignant Lymphoma.

Results 1 - 8 of 8

Managing HL would like to recognize and thank Merck & Co., Inc., Seattle Genetics, and Takeda Oncology for their educational support of ManagingHodgkinLymphoma.com

©2017 MediCom Worldwide, Inc. All rights reserved